Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Coagulation Factor VIIa variant · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Coagulation Factor VIIa variant | BIOLOGICAL | Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required. |
Coagulation Factor VIIa variant is being studied for the treatment of hemophilia A with inhibitor. It is an investigational therapy in clinical development, and it is not yet approved for commercial use.
Coagulation Factor VIIa variant is being developed by Gyre Therapeutics, Inc., a company traded on the stock exchange under the ticker GYRE.
Coagulation Factor VIIa variant is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
Coagulation Factor VIIa variant has been studied in a completed Phase 2 clinical trial with the identifier NCT03407651. The trial enrolled 11 participants and evaluated the drug in adults with hemophilia A with inhibitor.
Yes, Coagulation Factor VIIa variant is also known as Marzeptacog Alfa (Activated). The clinical trial NCT03407651 studied this variant in subjects with hemophilia A and B.